

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/9/2001. Amended 01/01/11

Name of Entity:	Chimeric Therapeutics Limited (ASX: CHM)
ABN:	68 638 835 828

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director:	Paul Hopper
Date of Last Notice:	8 April 2024

Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or Indirect Interest	Direct and Indirect														
Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest.	Director related parties														
Date of change	(a) 9 December 2024 (b) 10 December 2024 (c) 13 December 2024														
No. of securities held prior to change	<table><tr><td></td><td>Shares</td><td>Options</td></tr><tr><td>Direct</td><td>1,232,142</td><td>-</td></tr><tr><td>Indirect</td><td>93,762,432</td><td>-</td></tr><tr><td>Total</td><td>94,994,574</td><td>-</td></tr></table>				Shares	Options	Direct	1,232,142	-	Indirect	93,762,432	-	Total	94,994,574	-
	Shares	Options													
Direct	1,232,142	-													
Indirect	93,762,432	-													
Total	94,994,574	-													
Class	(a) Ordinary shares (b),(c) CHMAY unlisted options														
Number acquired	<table><tr><td></td><td>Shares</td><td>Options</td></tr><tr><td>Direct</td><td>20,000,000</td><td>31,580,882</td></tr><tr><td>Indirect</td><td>80,000,000</td><td>80,000,000</td></tr><tr><td>Total</td><td>100,000,000</td><td>111,580,882</td></tr></table>				Shares	Options	Direct	20,000,000	31,580,882	Indirect	80,000,000	80,000,000	Total	100,000,000	111,580,882
	Shares	Options													
Direct	20,000,000	31,580,882													
Indirect	80,000,000	80,000,000													
Total	100,000,000	111,580,882													
Number disposed	<table><tr><td></td><td>Shares</td><td>Options</td></tr><tr><td>Direct</td><td>-</td><td>-</td></tr><tr><td>Indirect</td><td>-</td><td>-</td></tr><tr><td>Total</td><td>-</td><td>-</td></tr></table>				Shares	Options	Direct	-	-	Indirect	-	-	Total	-	-
	Shares	Options													
Direct	-	-													
Indirect	-	-													
Total	-	-													

+ See chapter 19 for defined terms.

Appendix 3Y

Change of Director's Interest Notice

Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation	(a) A\$0.008 per ordinary share (b),(c) Nil consideration for unlisted options												
No. of securities held after change	<table><tr><td></td><td>Shares</td><td>Options</td></tr><tr><td>Direct</td><td>21,232,142</td><td>31,580,882</td></tr><tr><td>Indirect</td><td>173,762,432</td><td>80,000,000</td></tr><tr><td>Total</td><td>194,994,574</td><td>111,580,882</td></tr></table>		Shares	Options	Direct	21,232,142	31,580,882	Indirect	173,762,432	80,000,000	Total	194,994,574	111,580,882
	Shares	Options											
Direct	21,232,142	31,580,882											
Indirect	173,762,432	80,000,000											
Total	194,994,574	111,580,882											
Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	(a),(c) Participation in Placement approved @ EGM 4 December 2024 (100,000,000 ordinary shares and 100,000,000 unlisted options) (b) Unlisted options issued under the Company’s Omnibus Incentive Plan. approved @ AGM 12 November 2024												

Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

Detail of contract	N/A
Nature of interest	N/A
Name of registered holder (if issued securities)	N/A
Date of change	N/A
No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed	N/A
Interest acquired	N/A
Interest disposed	N/A
Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation	N/A
Interest after change	N/A

+ See chapter 19 for defined terms.

Part 3 – Closed period

Were the interests in the securities or contracts detailed above traded during a +closed period where prior written clearance was required?	No
If so, was prior written clearance provided to allow the trade to proceed during this period?	N/A
If prior written clearance was provided, on what date was this provided?	N/A

+ See chapter 19 for defined terms.